ERBB2 and breast cancer: For this reason, an increase in plasma glutamine levels of HER2-negative breast cancer patients 2 weeks after completion of doxorubicin treatment was likely due to a compensatory mechanism to ameliorate doxorubicin-induced systemic oxidative stress.